D. E. Shaw & Co. Inc. Trims Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

D. E. Shaw & Co. Inc. decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 14.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 178,280 shares of the company's stock after selling 30,261 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 0.57% of Medpace worth $59,230,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Pallas Capital Advisors LLC lifted its holdings in Medpace by 179.7% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company's stock worth $1,086,000 after purchasing an additional 2,101 shares in the last quarter. Barclays PLC raised its holdings in shares of Medpace by 71.9% in the 3rd quarter. Barclays PLC now owns 19,781 shares of the company's stock valued at $6,603,000 after acquiring an additional 8,275 shares in the last quarter. Sanctuary Advisors LLC raised its holdings in shares of Medpace by 20.5% in the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock valued at $1,738,000 after acquiring an additional 844 shares in the last quarter. SYM FINANCIAL Corp purchased a new stake in shares of Medpace in the 4th quarter valued at about $320,000. Finally, Tokio Marine Asset Management Co. Ltd. purchased a new stake in shares of Medpace in the 4th quarter valued at about $9,335,000. Institutional investors own 77.98% of the company's stock.

Medpace Price Performance

Medpace stock traded up $17.71 during trading hours on Monday, reaching $313.74. The company had a trading volume of 321,078 shares, compared to its average volume of 346,665. The company has a 50-day moving average price of $306.60 and a 200 day moving average price of $328.47. The firm has a market cap of $9.02 billion, a price-to-earnings ratio of 24.84, a P/E/G ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. The business had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same period in the previous year, the firm earned $3.20 EPS. As a group, research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the business's stock in a transaction that occurred on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the transaction, the director now directly owns 2,998 shares of the company's stock, valued at approximately $904,856.36. The trade was a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 20.30% of the company's stock.

Analyst Ratings Changes

Several analysts have weighed in on MEDP shares. TD Cowen cut Medpace from a "buy" rating to a "hold" rating and lowered their price target for the company from $370.00 to $328.00 in a report on Monday, April 14th. Leerink Partners started coverage on Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target on the stock. William Blair reaffirmed a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Robert W. Baird lowered their price target on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. Finally, Truist Financial reduced their price objective on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research report on Wednesday, April 23rd. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $349.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.